MAGNAM Trial, Magnesium Versus Amiodarone in AF in Critical Care
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
A multi-centre, non-blinded, comparative effectiveness, randomised controlled trial. Patients
will be prospectively enrolled from Critical Care Units and will be assessed for study
enrollment based on inclusion/exclusion criteria at the time of the onset of fast atrial
fibrillation( irregular and often rapid heart rate). The authors hypothesize that high dose
Magnesium Sulphate with the addition of Digoxin as a second line treatment will improve the
success rate in returning the heart to normal rhythm as well as speed of resolution of
critical illness in new onset rapid atrial fibrillation in the critically ill cared for in
general ICUs.